Bakris, George L., 1952-
Bakris, George L.
George Bakris
Bakris, George L., 19..-...., médecin
Bakris, George
VIAF ID: 315209477 (Personal)
Permalink: http://viaf.org/viaf/315209477
Preferred Forms
-
-
- 100 1 _ ‡a Bakris, George L.
-
-
-
-
- 100 1 _ ‡a Bakris, George L. ‡d 1952-
- 100 1 _ ‡a Bakris, George L. ‡d 1952-
- 100 1 _ ‡a Bakris, George L. ‡d 1952-
- 100 1 _ ‡a Bakris, George L., ‡d 19..-...., ‡c médecin
-
-
-
- 100 1 _ ‡a Bakris, George L., ‡d 1952-
- 100 0 _ ‡a George Bakris
4xx's: Alternate Name Forms (4)
5xx's: Related Names (4)
- 510 2 _ ‡a Health Science Center
- 510 2 _ ‡a Health Science Center ‡g San Antonio, Tex. ‡e Affiliation
- 510 2 _ ‡a Medical Center
- 510 2 _ ‡a Medical Center ‡g Chicago, Ill. ‡e Affiliation
Works
Title | Sources |
---|---|
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guideli | |
Are All Patients With Type 1 Diabetes Destined for Dialysis if They Live Long Enough? Probably Not. | |
ASH 2000 compte-rendu du 15ème congrès de l'American society of hypertension in New York City | |
Baseline characteristics and enrichment results of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial. | |
Big Topics for DIabetes Care in 2018: Clinical Guidelines, Costs of Diabetes, and Information Technology | |
Blood pressure reduced to new guideline goals in patients with high-normal glucose further reduces cardiovascular events. | |
Body weight changes with beta-blocker use: results from GEMINI. | |
Cardiovascular protection for all individuals at high risk: evidence-based best practice | |
Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial | |
Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension | |
Czy u wszystkich chorych na cukrzycę typu 2 należy od początku stosować skojarzone leczenie hipotensyjne? | |
Czy warto hamować układ renina-angiotensyna u chorych na cukrzycę typu 1? | |
Diabetes and hypertension : evaluation and management | |
Diabetic Kidney Disease: A Determinant of Cardiovascular Risk in Type 1 Diabetes | |
Diastolic Blood Pressure Does Not Influence Cardiovascular Outcomes in Type 2 Diabetes; or Does It? | |
Evolution of Patiromer Use: a Review | |
Ewolucja wytycznych leczenia nefropatii cukrzycowej | |
Hoće li rezultati STAR ispitivanja promijeniti pristup liječenju hipertoničara s metaboličkim sindromom? | |
Hyperkalaemia in diabetes: a silent risk predicting poor outcomes | |
Hypertension : a clinician's guide to diagnosis and treatment | |
Hypertension : a companion to Braunwald's heart disease | |
Hypertension : principles and practice | |
Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia | |
Inhibiting the renin-angiotensin system in patients with type 1 diabetes : is it worth it? | |
Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: a post-hoc analysis of the SONAR trial | |
International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension | |
The kidney in heart failure | |
Kidney injury is not prevented by hydration alone | |
Kliniczne znaczenie mikroalbuminurii w cukrzycy i nadciśnieniu tętniczym : program edukacyjny : hipertensjologia | |
Leki hipotensyjne a insulinowrażliwość i rozwój cukrzycy | |
Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease | |
Lower extremity arterial disease | |
Managing Diabetic Nephropathies in Clinical Practice | |
Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial | |
Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice | |
Nadciśnienie tętnicze : diagnostyka i leczenie / Barry J. Sobel, George L. Bakris. - Kraków, cop. 1997. | |
New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval | |
Non-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease | |
Olmesartan-based monotherapy vs combination therapy in hypertension: A meta-analysis based on age and chronic kidney disease status. | |
Oral potassium supplement use and outcomes in chronic heart failure: a propensity-matched study | |
The past, present and future of renin-angiotensin aldosterone system inhibition | |
Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL | |
Predictors of blood pressure response in the SYMPLICITY HTN-3 trial | |
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON). | |
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial | |
Renin-Angiotensin system in diabetic nephropathy: from bench to bedside 12 tables | |
Results of ACCORDIAN in ACCORD with lower blood pressure begetting lower mortality in patients with diabetes. | |
Rozpoznawanie, patogeneza i leczenie cukrzycowej choroby nerek w różnych stadiach zaawansowania u pacjentów z cukrzycą typu 2 | |
Severe menses-associated hypertension successfully treated with gonadotropin-releasing hormone agonist. | |
Uncontrolled hypertension and increased risk for incident heart failure in older adults with hypertension: findings from a propensity-matched prospective population study |